Open AccessKEYNOTE-921: Phase III study of pembrolizumab plus docetaxel for metastatic castration-resistant prostate cancer
Author(s) -
Daniel P. Petrylak,
Raffaele Ratta,
Rustem Gafanov,
Gaetano Facchini,
Josep María Piulats,
Gero Kramer,
Thomas W. Flaig,
Sreenivasa R Chandana,
Ben Li,
Joseph E. Burgents,
Karim Fizazi
Publication year - 2021
Publication title -
future oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.857
H-Index - 72
eISSN - 1744-8301
pISSN - 1479-6694
DOI - 10.2217/fon-2020-1133
Subject(s) - docetaxel , medicine , enzalutamide , pembrolizumab , prostate cancer , oncology , abiraterone acetate , prednisone , cancer , clinical trial , androgen deprivation therapy , immunotherapy , androgen receptor
Despite recent advances, treatment options for men with metastatic castration-resistant prostate cancer (mCRPC) progressing after next-generation hormonal agents (NHAs) are limited and provide only modest survival benefit. Thus, an unmet need remains for mCRPC patients after treatment with targeted endocrine therapy or NHA therapy. Pembrolizumab, a humanized monoclonal antibody for PD-1, has been found to have activity as monotherapy in patients with mCRPC and as combination therapy in a Phase Ib/II study with docetaxel and prednisone/prednisolone for patients previously treated with enzalutamide or abiraterone acetate. The aim of the randomized, double-blind, Phase III KEYNOTE-921 study is to evaluate the efficacy and safety of pembrolizumab plus docetaxel in patients with mCRPC who were previously treated with an NHA. Clinical trial registration: NCT03834506 ( ClinicalTrials.gov )